Ajanta Pharma's Q3 FY 2025-26 Quarterly Results
- 31 Jan 2026
Result Summary
- Ajanta Pharma Ltd reported a 0.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 19.0%.
- Its expenses for the quarter were down by 2.9% QoQ and up 19.8% YoY.
- The net profit increased 5.2% QoQ and increased 17.6% YoY.
- The earnings per share (EPS) of Ajanta Pharma Ltd stood at 21.91 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 1399.81 | 1413.07 | 1176.57 | -0.9% | 19.0% |
Total Expenses | 1041.21 | 1072.26 | 869.18 | -2.9% | 19.8% |
Profit Before Tax | 358.60 | 340.81 | 307.39 | 5.2% | 16.7% |
Tax | 84.83 | 80.62 | 74.51 | 5.2% | 13.9% |
Profit After Tax | 273.77 | 260.19 | 232.88 | 5.2% | 17.6% |
Earnings Per Share | 21.91 | 20.82 | 18.59 | 5.2% | 17.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Ajanta Pharma Ltd is a renowned pharmaceutical company engaged in the development, manufacturing, and marketing of quality finished dosages. It operates predominantly in the pharmaceutical industry, offering a wide range of products across various therapeutic segments like cardiology, dermatology, ophthalmology, and pain management. The company is known for its strong presence in emerging markets and a robust portfolio of specialty generics. Ajanta Pharma has been actively involved in expanding its global footprint, with significant operations in India, Africa, and the United States. The company focuses on innovation-driven growth, with a commitment to delivering affordable healthcare solutions. No recent major developments are available in the data provided.
Revenue
During the third quarter of the financial year 2026 (Q3FY26), Ajanta Pharma Ltd reported a total income of ₹1399.81 crores. This represents a slight quarter-over-quarter (QoQ) decline of 0.9% compared to ₹1413.07 crores in the second quarter of FY26 (Q2FY26). However, the year-over-year (YoY) comparison shows a substantial growth of 19.0% from ₹1176.57 crores in the same quarter of the previous year (Q3FY25). This upward trend in YoY revenue indicates the company's growing market presence and sales volume over the past year, despite the marginal QoQ decrease.
Profitability
Ajanta Pharma Ltd's profitability metrics demonstrate a strong financial performance in Q3FY26. The company achieved a profit before tax of ₹358.60 crores, reflecting a 5.2% QoQ increase from ₹340.81 crores in Q2FY26 and a 16.7% YoY rise from ₹307.39 crores in Q3FY25. The tax expense for the quarter stood at ₹84.83 crores, maintaining the same QoQ growth rate of 5.2%, which aligns with the increase in profit before tax. The profit after tax for Q3FY26 amounted to ₹273.77 crores, marking a 5.2% QoQ and a 17.6% YoY increase. These figures highlight the company's efficient cost management and enhanced profitability over the periods analyzed.
Operating Metrics
Ajanta Pharma Ltd's operating metrics for Q3FY26 reveal a total expense of ₹1041.21 crores, which decreased by 2.9% QoQ from ₹1072.26 crores in Q2FY26 but increased by 19.8% YoY from ₹869.18 crores in Q3FY25. This indicates a reduction in expenses in the recent quarter compared to the previous quarter, while still reflecting a significant YoY rise. The Earnings Per Share (EPS) for Q3FY26 was ₹21.91, up by 5.2% QoQ from ₹20.82 in Q2FY26 and by 17.9% YoY from ₹18.59 in Q3FY25. The continuous increase in EPS suggests enhanced shareholder value over the periods. The analysis of these metrics demonstrates the company's operational efficiency and its ability to sustain profit growth through effective cost control.